News for Hologic, Inc. (HOLX)

Get a deeper insight into the potential performance of Hologic (HOLX) for the quarter ended June 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for some of its key metrics.

The C-suite leaders discuss how collaboration between finance and marketing supports long-term growth.

West Pharmaceutical Services, Inc. (WST) has announced the appointment of Robert McMahon as the new Senior Vice President and Chief Financial Officer, effecti

The Global Economic Conditions Survey reflects a new phase of concern among accounting professionals.

Summary West Pharmaceutical Services Inc (WST), a global leader in innovative solutions for injectable drug administration, announced on July 21, 2025, the appo

PR NewswireEXTON, Pa., July 21, 2025 EXTON, Pa., July 21, 2025 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovativ

West Pharmaceutical Services (WST) appoints Robert McMahon as new CFO, effective August 4, 2025. McMahon brings 34 years of healthcare industry experien

Hologic, Inc. (HOLX), a Delaware corporation, has announced the successful refinancing of its term loan and revolving credit facility. The company, along with

On July 16, 2025, Mizuho analyst Anthony Petrone reaffirmed his confidence in Hologic (HOLX) by maintaining an "Outperform" rating. The analyst also increased t

Mizuho has revised its price target for Hologic (HOLX), increasing it from $65 to $70 while maintaining an Outperform rating. The adjustment comes as the firm r

Hologic is scheduled to report its third-quarter results later this month, and analysts are projecting a marginal decline in profits.

Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.

In a recent update, Citigroup analyst Patrick Donnelly has upgraded Hologic (HOLX) from a "Neutral" to a "Buy" rating. This change reflects increased confidence

Citi has elevated its rating for Hologic (HOLX) from Neutral to Buy, raising the price target significantly from $60 to $80. The upgrade follows a recent potent

Recently, Zacks.com users have been paying close attention to Hologic (HOLX). This makes it worthwhile to examine what the stock has in store.

Summary Hologic Inc (HOLX), a leading medical technology company focused on women's health, has announced that it will release its financial results for the thi

Hologic, Inc. (HOLX) to announce Q3 fiscal 2025 results on July 30, 2025. Conference call scheduled at 4:30 p.m. Eastern Time. Webcast replay availab

Hologic (HOLX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Hologic has outpaced its healthcare equipment peers over the past year, with analysts maintaining a moderately bullish outlook on the stock’s future performance.